Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 1266-1292

  Wang, Na Na ^a   Li, Zhi Heng ^a   Zhao, He ^a   Tao, Yan Fang ^a   Xu, Li Xiao ^a   Lu, Jun ^a   Cao, Lan ^a   Du, Xiao Juan ^b   Sun, Li Chao ^c   Zhao, Wen Li ^a   Xiao, Pei Fang ^a   Fang, Fang ^a   Su, Guang Hao ^a   Li, Yan Hong ^a   Li, Gang ^a   Li, Yi Ping ^a   Xu, Yun Yun ^a   Zhou, Hui Ting ^a   Wu, Yi ^a   Jin, Mei Fang ^a   Liu, Lin ^a   Ni, Jian ^d   Wang, Jian ^a   Hu, Shao Yan ^a   Zhu, Xue Ming ^a   Feng, Xing ^a   Pan, Jian ^a   more..

^a CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Department of Gastroenterology The 5th Hospital of Chinese People s Liberation Army (PLA)   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Oncogene target; Pediatric acute myeloid leukemia (AML); Polo like kinase 1 (PLK1); RO3280

Indexed keywords

BRUTON TYROSINE KINASE; CASPASE 3; CASPASE 9; CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOCORTIN 5; MESSENGER RNA; NETRIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE C ZETA; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RO3280; SUPPRESSOR OF CYTOKINE SIGNALING 2; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW; CELL CYCLE; CELL GROWTH; CELL LYSATE; CELL PROLIFERATION; CELL VIABILITY; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE CONTROL; HUMAN; HUMAN CELL; IC50; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SURVIVAL; UPREGULATION; WESTERN BLOTTING; ACUTE MYELOBLASTIC LEUKEMIA; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; CLUSTER ANALYSIS; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFECTS; HL 60 CELL LINE; K562 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; AZEPINES; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; DNA FRAGMENTATION; DOWN-REGULATION; FEMALE; HL-60 CELLS; HUMANS; K562 CELLS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84920911049     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16011266     Document Type: Article

References (53)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer statistics. CA Cancer J. Clin. 2002, 52, 23–47.
2. Jabbour, E.; Cortes, J.; Ravandi, F.; O’Brien, S.; Kantarjian, H. Targeted therapies in hematology and their impact on patient care: Chronic and acute myeloid leukemia. Semin. Hematol. 2013, 50, 271–283.
3. Miano, M.; Micalizzi, C.; Calvillo, M.; Dufour, C. New targets in pediatric acute myeloid leukemia. Immunol. Lett. 2013, 155, 47–50.
4. Zhao, Y.; Huang, H.; Wei, G. Novel agents and biomarkers for acute lymphoid leukemia. J. Hematol. Oncol. 2013, 6, 40.
5. Moore, A.S.; Kearns, P.R.; Knapper, S.; Pearson, A.D.; Zwaan, C.M. Novel therapies for children with acute myeloid leukaemia. Leukemia 2013, 27, 1451–1460.
6. Lancet, J.E. New agents: Great expectations not realized. Best Pract. Res. Clin. Haematol. 2013, 26, 269–274.
7. Ostronoff, F.; Estey, E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin. Investig. Drugs 2013, 22, 1659–1669.
8. Hales, E.C.; Taub, J.W.; Matherly, L.H. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell. Signal. 2014, 26, 149–161.
9. Vitagliano, O.; Addeo, R.; D’Angelo, V.; Indolfi, C.; Indolfi, P.; Casale, F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: Implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev. Hematol. 2013, 6, 587–597.
10. Peloquin, G.L.; Chen, Y.B.; Fathi, A.T. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013, 4, 735–746.
11. Smith, C.C.; Shah, N.P. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am. Soc. Clin. Oncol. Educ. Book 2013, doi:10.1200/EdBook_AM.2013.33.313.
12. Hatzimichael, E.; Georgiou, G.; Benetatos, L.; Briasoulis, E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am. J. Blood Res. 2013, 3, 29–51.
13. Gjertsen, B.T.; Schoffski, P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2014, doi:10.1038/leu.2014.222.
14. Tsykunova, G.; Reikvam, H.; Ahmed, A.B.; Nepstad, I.; Gjertsen, B.T.; Bruserud, O. Targeting of polo-like kinases and their cross talk with Aurora kinases—Possible therapeutic strategies in human acute myeloid leukemia? Expert Opin. Investig. Drugs 2012, 21, 587–603.
15. Wasch, R.; Hasskarl, J.; Schnerch, D.; Lubbert, M. BI2536—Targeting the mitotic kinase Polo-like kinase 1 (PLK1). In Small Molecules in Oncology; Springer Berlin Heidelberg: Berlin, Germany, 2010; Volume 184, pp. 215–218.
16. Zhang, Z.; Zhang, G.; Kong, C. High expression of Polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol. Oncol.2013, 31, 1222–1230.
17. Zhang, G.; Zhang, Z.; Liu, Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol.2013, 34, 1887–1894.
18. Maire, V.; Nemati, F.; Richardson, M.; Vincent-Salomon, A.; Tesson, B.; Rigaill, G.; Gravier, E.; Marty-Prouvost, B.; de Koning, L.; Lang, G. et al. Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2013, 73, 813–823.
19. Deeraksa, A.; Pan, J.; Sha, Y.; Liu, X.D.; Eissa, N.T.; Lin, S.H.; Yu-Lee, L.Y. PLK1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 2013, 32, 2973–2983.
20. Ackermann, S.; Goeser, F.; Schulte, J.H.; Schramm, A.; Ehemann, V.; Hero, B.; Eggert, A.; Berthold, F.; Fischer, M. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin. Cancer Res. 2011, 17, 731–741.
21. Pellegrino, R.; Calvisi, D.F.; Ladu, S.; Ehemann, V.; Staniscia, T.; Evert, M.; Dombrowski, F.; Schirmacher, P.; Longerich, T. Oncogenic and tumor suppressive roles of Polo-like kinases in human hepatocellular carcinoma. Hepatology 2010, 51, 857–868.
22. Zhang, Y.; Liu, Y.; Yang, Y.X.; Xia, J.H.; Zhang, H.X.; Li, H.B.; Yu, C.Z. The expression of PLK-1 in cervical carcinoma: A possible target for enhancing chemosensitivity. J. Exp. Clin. Cancer Res. 2009, 28, 130.
23. Schmit, T.L.; Zhong, W.; Nihal, M.; Ahmad, N. Polo-like kinase 1 (PLK1) in non-melanoma skin cancers. Cell Cycle 2009, 8, 2697–2702.
24. Renner, A.G.; Dos Santos, C.; Recher, C.; Bailly, C.; Creancier, L.; Kruczynski, A.; Payrastre, B.; Manenti, S. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009, 114, 659–662.
25. Zhang, Y.; Du, X.L.; Wang, C.J.; Lin, D.C.; Ruan, X.; Feng, Y.B.; Huo, Y.Q.; Peng, H.; Cui, J.L.; Zhang, T.T. et al. Reciprocal activation between PLK1 and STAT3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology 2012, 142, 521–530.
26. Behren, A.; Muhlen, S.; Acuna Sanhueza, G.A.; Schwager, C.; Plinkert, P.K.; Huber, P.E.; Abdollahi, A.; Simon, C. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene 2010, 29, 1519–1530.
27. Malumbres, M. Preclinical models for cell cycle-targeted therapies. Adv. Exp. Med. Biol. 2006, 587, 139–147.
28. Valsasina, B.; Beria, I.; Alli, C.; Alzani, R.; Avanzi, N.; Ballinari, D.; Cappella, P.; Caruso, M.; Casolaro, A.; Ciavolella, A. et al. NMS-P937, an orally available, specific small-molecule Polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol. Cancer Ther. 2012, 11, 1006–1016.
29. Hikichi, Y.; Honda, K.; Hikami, K.; Miyashita, H.; Kaieda, I.; Murai, S.; Uchiyama, N.; Hasegawa, M.; Kawamoto, T.; Sato, T. et al. TAK-960, a novel, orally available, selective inhibitor of Polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol. Cancer Ther. 2012, 11, 700–709.
30. Chen, S.; Bartkovitz, D.; Cai, J.; Chen, Y.; Chen, Z.; Chu, X.J.; Le, K.; Le, N.T.; Luk, K.C.; Mischke, S. et al. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Bioorgan. Med. Chem. Lett. 2012, 22, 1247–1250.
31. Gumireddy, K.; Reddy, M.V.; Cosenza, S.C.; Boominathan, R.; Baker, S.J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E.P. ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent. Cancer Cell 2005, 7, 275–286.
32. Oliveira, J.C.; Pezuk, J.A.; Brassesco, M.S.; Morales, A.G.; Queiroz, R.G.; Scrideli, C.A.; Tone, L.G. PLK1 expression and BI2536 effects in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 2014, 61, 1227–1231.
33. Dasmahapatra, G.; Patel, H.; Nguyen, T.; Attkisson, E.; Grant, S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 2013, 19, 404–414.
34. Ikezoe, T.; Yang, J.; Nishioka, C.; Takezaki, Y.; Tasaka, T.; Togitani, K.; Koeffler, H.P.; Yokoyama, A. A novel treatment strategy targeting Polo-like kinase 1 in hematological malignancies. Leukemia 2009, 23, 1564–1576.
35. Berg, T.; Bug, G.; Ottmann, O.G.; Strebhardt, K. Polo-like kinases in AML. Expert Opin. Investig. Drugs 2012, 21, 1069–1074.
36. Stadler, W.M.; Vaughn, D.J.; Sonpavde, G.; Vogelzang, N.J.; Tagawa, S.T.; Petrylak, D.P.; Rosen, P.; Lin, C.C.; Mahoney, J.; Modi, S. et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 2014, 120, 976–982.
37. Lin, C.C.; Su, W.C.; Yen, C.J.; Hsu, C.H.; Su, W.P.; Yeh, K.H.; Lu, Y.S.; Cheng, A.L.; Huang, D.C.; Fritsch, H. et al. A phase I study of two dosing schedules of volasertib (BI6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br. J. Cancer 2014, 110, 2434–2440.
38. Wagenblast, J.; Hirth, D.; Thron, L.; Arnoldner, C.; Diensthuber, M.; Stover, T.; Hambek, M. Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck. Oncol. Lett.2012, 4, 175–177.
39. Nie, Z.; Feher, V.; Natala, S.; McBride, C.; Kiryanov, A.; Jones, B.; Lam, B.; Liu, Y.; Kaldor, S.; Stafford, J. et al. Discovery of TAK-960: An orally available small molecule inhibitor of Polo-like kinase 1 (PLK1). Bioorg. Med. Chem. Lett. 2013, 23, 3662–3666.
40. Oussenko, I.A.; Holland, J.F.; Reddy, E.P.; Ohnuma, T. Effect of ON 01910. Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res. 2011, 71, 4968–4976.
41. Bowles, D.W.; Diamond, J.R.; Lam, E.T.; Weekes, C.D.; Astling, D.P.; Anderson, R.T.; Leong, S.; Gore, L.; Varella-Garcia, M.; Vogler, B.W. et al. Phase I study of oral rigosertib (ON 01910. Na), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies. Clin. Cancer Res.2014, 20, 1656–1665.
42. Garuti, L.; Roberti, M.; Bottegoni, G. Polo-like kinases inhibitors. Curr. Med. Chem.2012, 19, 3937–3948.
43. Schmittgen, T.D.; Lee, E.J.; Jiang, J. High-throughput real-time PCR. Methods Mol. Biol. 2008, 429, 89–98.
44. Liu, X. PLK1, a negative regulator of p21. Cell Cycle 2009, 8, 336–337.
45. Kreis, N.N.; Louwen, F.; Zimmer, B.; Yuan, J. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Oncotarget 2014, in press.
46. Driscoll, D.L.; Chakravarty, A.; Bowman, D.; Shinde, V.; Lasky, K.; Shi, J.; Vos, T.; Stringer, B.; Amidon, B.; D’Amore, N. et al.PLK1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines. PLoS One 2014, 9, e111060.
47. Thalhammer, V.; Lopez-Garcia, L.A.; Herrero Martin, D.; Hecker, R.; Laubscher, D.; Gierisch, M.E.; Wachtel, M.; Bode, P.; Nanni, P.; Blank, B. et al. PLK1 phosphorylates PAX3-FOXO1 the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res. 2014, doi:10.1158/0008-5472.
48. Zhao, J.; Jitkaew, S.; Cai, Z.; Choksi, S.; Li, Q.; Luo, J.; Liu, Z.G. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. USA 2012, 109, 5322–5327.
49. Haddick, P.C.; Tom, I.; Luis, E.; Quinones, G.; Wranik, B.J.; Ramani, S.R.; Stephan, J.P.; Tessier-Lavigne, M.; Gonzalez, L.C. Defining the ligand specificity of the deleted in colorectal cancer (DCC) receptor. PLoS One 2014, 9, e84823.
50. Meimei, L.; Peiling, L.; Baoxin, L.; Changmin, L.; Rujin, Z.; Chunjie, H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med. Oncol. 2011, 28, 282–289.
51. Inohara, N.; Ding, L.; Chen, S.; Nunez, G. harakiri, A novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins BCL-2 and BCL-XL. EMBO J. 1997, 16, 1686–1694.
52. Choi, B.; Pagano, M.; Dai, W. PLK1 phosphorylates PTEN and regulates its mitotic activity during the cell cycle. J. Biol. Chem. 2014, 20, 14066–14074.
53. Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55, 611–622.